"Placebos" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.
| Descriptor ID |
D010919
|
| MeSH Number(s) |
D26.660 E02.785
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Placebos".
Below are MeSH descriptors whose meaning is more specific than "Placebos".
This graph shows the total number of publications written about "Placebos" by people in this website by year, and whether "Placebos" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 8 | 8 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 10 | 10 |
| 2006 | 0 | 8 | 8 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 8 | 8 |
| 2009 | 1 | 9 | 10 |
| 2010 | 1 | 11 | 12 |
| 2011 | 0 | 15 | 15 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 8 | 8 |
| 2015 | 0 | 6 | 6 |
| 2016 | 0 | 5 | 5 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 3 | 4 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Placebos" by people in Profiles.
-
Gene Therapy for Leber's Hereditary Optic Neuropathy: Time to Include a True Placebo Arm? Am J Ophthalmol. 2022 09; 241:A11-A12.
-
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021 12; 27(12):2224-2233.
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1?+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec; 17(34):4665-4676.
-
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724.
-
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
-
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021 Aug; 17(22):2923-2939.
-
Selective serotonin re-uptake inhibitors for premature ejaculation in adult men. Cochrane Database Syst Rev. 2021 03 21; 3:CD012799.
-
Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 02 25; 2:CD010668.
-
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021 05; 14(3):1176-1184.